Lifecore Biomedical Files 8-K on Financials
Ticker: LFCR · Form: 8-K · Filed: Aug 26, 2024 · CIK: 1005286
| Field | Detail |
|---|---|
| Company | Lifecore Biomedical, Inc. \De\ (LFCR) |
| Form Type | 8-K |
| Filed Date | Aug 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, financial-reporting
TL;DR
Lifecore Biomedical filed an 8-K for financial updates.
AI Summary
On August 26, 2024, Lifecore Biomedical, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing indicates Lifecore Biomedical is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial risks or operational changes.
Key Players & Entities
- Lifecore Biomedical, Inc. (company) — Registrant
- August 26, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of incorporation
- Chaska, Minnesota (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Lifecore Biomedical, Inc.?
The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
On what date was this 8-K report filed?
The report was filed on August 26, 2024.
In which state is Lifecore Biomedical, Inc. incorporated?
Lifecore Biomedical, Inc. is incorporated in Delaware.
What is the address of Lifecore Biomedical, Inc.'s principal executive offices?
The principal executive offices are located at 3515 Lyman Boulevard, Chaska, Minnesota 55318.
Does the filing mention any former company names or addresses?
Yes, the filing notes that the former company name was Landec Corp \CA\, with a date of name change on December 22, 1995.
Filing Stats: 539 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-08-26 17:26:20
Filing Documents
- lndc-20240826.htm (8-K) — 29KB
- lfcrq4fy24earningsrelease.htm (EX-99.1) — 381KB
- 0001005286-24-000125.txt ( ) — 559KB
- lndc-20240826.xsd (EX-101.SCH) — 2KB
- lndc-20240826_lab.xml (EX-101.LAB) — 21KB
- lndc-20240826_pre.xml (EX-101.PRE) — 12KB
- lndc-20240826_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 26, 2024, Lifecore Biomedical, Inc. (the "Company") issued a press release announcing its consolidated financial results for the fourth quarter and full year of fiscal 2024 ended May 26, 2024. The press release is furnished herewith as Exhibit 99.1. The information in this Item 2.02 of this Current Report, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that Section. The information in this Item 2.02 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished as part of this report: Exhibit No. Description 99.1 Press Release dated August 26, 2024. 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 26, 2024 LIFECORE BIOMEDICAL, INC. By: /s/ John D. Morberg John D. Morberg Executive Vice President and Chief Financial Officer